Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer
This study is currently recruiting patients.
Verified by National Cancer Institute (NCI) November 2006
| Sponsors and Collaborators: |
University of California, San Francisco
|
| Information provided by: |
National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: |
NCT00402285 |
|
Purpose
RATIONALE: The use of lycopene, a substance found in tomatoes, or omega-3 fatty acid nutritional supplements may keep cancer from growing in patients with prostate cancer.
PURPOSE: This randomized clinical trial is studying lycopene to see how well it works compared to omega-3 fatty acids or a placebo in treating patients with stage I or stage II prostate cancer.
| Condition |
Intervention |
Prostate Cancer
|
Drug: lycopene
Drug: omega-3 fatty acids
Procedure: biologically based therapies
Procedure: biopsies
Procedure: cancer prevention intervention
Procedure: complementary and alternative therapy
Procedure: diagnostic test
Procedure: dietary intervention
Procedure: gene expression
Procedure: gene expression profiling
Procedure: nutritional supplementation
Procedure: polymerase chain reaction
Procedure: quality-of-life assessment
Procedure: supportive care/therapy
|
MedlinePlus related topics: Prostate Cancer
Study Type: Interventional
Study Design: Treatment, Randomized, Placebo Control
Official Title: The Molecular Effects of Nutrition Supplements (MENS) Prostate Study
Further study details as provided by National Cancer Institute (NCI):
Primary Outcomes: Two-fold up or down change in mRNA transcript level in patients with stage I or II adenocarcinoma of the prostate treated on a nutritional supplement arm (lycopene or omega-3 fatty acids) vs placebo control arm
Secondary Outcomes: New candidate molecular targets for lycopene and omega-3 response pathways by cDNA microarray; Correlation of gene expression patterns (determined by cDNA array analysis) with self-reported dietary intake; Correlation of gene expression patterns (determined by cDNA array analysis) with disease progression or lack of progression at 12 months; Incidence of tumor progression
Expected Total Enrollment: 114
Study start: April 2003
OBJECTIVES:
Primary
- Compare gene expression in normal prostate tissue (at baseline and after treatment) of patients with stage I or II adenocarcinoma of the prostate treated with lycopene vs omega-3 fatty acid nutritional supplements vs placebo.
Secondary
- Determine new candidate molecular targets for lycopene and omega-3 response pathways.
- Correlate baseline gene expression patterns, determined by cDNA array analysis, with self-reported dietary intake.
- Correlate gene expression patterns with progression or lack of progression at 12 months after study entry.
- Determine if lycopene or omega-3 supplements affect the incidence of tumor progression.
OUTLINE: This is a randomized, placebo-controlled study. Patients are stratified according to dietary intake of tomato and fish (low tomato [< 4 servings/week], low fish [< 2 servings/week] vs low tomato, high fish [≥ 2 servings/week] vs high tomato [≥ 4 servings/week], low fish vs high tomato, high fish). Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients maintain normal diet and receive oral omega-3 fatty acids placebo 3 times daily and lycopene placebo twice daily.
- Arm II: Patients receive oral lycopene twice daily and oral omega-3 fatty acids placebo 3 times daily.
- Arm III: Patients receive oral lycopene placebo twice daily and oral omega-3 fatty acids 3 times daily.
In all arms, treatment continues for up to 90 days or until post-treatment biopsy is scheduled (a maximum of 104 days) in the absence of disease progression.
Patients complete a dietary questionnaire at baseline and then for 3 days each month during study therapy. Quality of life is assessed at baseline and at 3 months.
Prostate tissue needle biopsies and blood samples are collected at baseline and at 3 months. Tissue and blood samples are examined for lycopene and omega-3 fatty acids (treatment compliance), omega-6 fatty acids, insulin-like growth factor (IGF)-1, IGF binding protein-5, and cyclooxygenase-2 gene by polymerase chain reaction, cDNA microarray hybridization, and other gene expression assays.
After completion of study treatment, patients are followed every 3 months for 2 years.
PROJECTED ACCRUAL: A total of 114 patients will be enrolled in this study.
Eligibility
Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the prostate meeting the following criteria:
- Newly diagnosed disease
- Small cell acinar type
- Gleason score ≤ 6 with no pattern 4 or 5 histology
- Gleason pattern 4 seen as a microfocus (< 2 mm in length) allowed
- Stage I-II (T1 or T2a) disease
- Must have had an extended pattern biopsy (defined as 8+ cores) within the past 2 years
- Patients meeting all of the eligibility criteria except for the aforementioned extended pattern biopsy within the past two years may enroll in the study if they have an extended pattern clinical biopsy scheduled no more than 6 weeks before beginning study treatment AND are willing to have an additional 4 biopsy cores
- No more than 33% of biopsy cores positive
- 33% or more of biopsy cores positive due to microfoci of adenocarcinoma allowed
- No more than 50% of the length of a tumor core involved by carcinoma
- Watchful waiting planned as primary treatment strategy
- Must have 3 serum prostate-specific antigen (PSA) level readings taken ≥ 2 weeks apart over the past year
- PSA ≤ 10.0 ng/mL
- PSA < 15 ng/mL in patients with benign prostatic hyperplasia or prostatitis allowed
- PSA doubling time ≥ 3 months
PATIENT CHARACTERISTICS:
- Life expectancy ≥ 3 months
- ECOG performance status 0-2
- No history of allergic reactions attributed to tomatoes, fish, soybean oil, gelatin capsules, or compounds of similar chemical or biologic composition to lycopene (carotenoids) or fish oil (omega-3 fatty acids)
- No uncontrolled intercurrent illness including, but not limited to, the following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness or social situations that would limit study compliance
PRIOR CONCURRENT THERAPY:
- No prior or concurrent treatment for prostate cancer, including surgery, radiation, hormonal therapy (e.g., leuprolide acetate, bicalutamide, flutamide, goserelin, megestrol, nilutamide, diethylstilbestrol/estrogen), chemotherapy, PC-SPES, or investigational agents
- More than 4 weeks since prior and no concurrent lycopene, fish oil (omega-3 fatty acids), or any other preparation intended to supplement levels of omega-3 unsaturated fatty acids
- More than 4 weeks since prior and no concurrent finasteride, dutasteride, saw palmetto or any other herbal/nutritional preparation indicated to affect hormone levels
- More than 1 month since prior nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, and/or aspirin for > 7 days duration
- No concurrent NSAIDs, COX-2 inhibitors, or aspirin
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00402285
California
UCSF Comprehensive Cancer Center, San Francisco, California, 94115, United States; Recruiting
Clinical Research Support Services 877-827-3222
Study chairs or principal investigators
Peter R. Carroll, MD, Study Chair, University of California, San Francisco
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Study ID Numbers: CDR0000505501; UCSF-03553; UCSF-H5664-22834-04A
Last Updated: November 20, 2006
Record first received: November 20, 2006
ClinicalTrials.gov Identifier:
NCT00402285
Health Authority: Unspecified
 
